

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>22102-002US1</b>	Application No. <b>09/623,533</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Bridon, et al.	
		Filing Date <b>September 5, 2000</b>	Group Art Unit <b>1648</b>

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,652,629	Mar. 24, 1987	Patrick et al.			
	AB	5,614,487	Mar. 25, 1997	Battersby et al.			
	AC	7,090,851	Aug. 15, 2006	Bridon et al.			
	AD	2005/0065075	Mar. 24, 2005	Erickson et al.			
	AE	2005/0070475	Mar. 31, 2005	Bridon et al.			
	AF	10/950,010	Sept. 24, 2004	Bridon et al.			
	AG						
	AH						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AI	WO 2005/108418	Nov. 17, 2005	WIPO			
	AJ	WO 2000/69902	Nov. 23, 2000	WIPO			
	AK	WO 1999/48536	Sept. 30, 1999	WIPO			
	AL	WO 1999/24075	May 20, 1999	WIPO			
	AM	WO 1999/24074	May 20, 1999	WIPO			
	AN	WO 1996/19495**	June 27, 1996	WIPO			
	AO	WO 1995/10302**	April 20, 1995	WIPO			
	AP						

\*\*Paper copy will be submitted via first class mail since reference is too large to submit electronically

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AQ	Archakov, Alexander I. et al. (2003) "Protein-Protein Interactions as a Target for Drugs in Proteomics," <i>Proteomics</i> , 3:380-391
	AR	Boeckler, Christophe "Immunogenicity of New Heterobifunctional Cross-Linking Reagents Used in the Conjugation...," <i>Journal of Immunological Methods</i> , (1996), Vol. 191:pp. 1-10
	AS	Chen, Chin-Ho et al. (June 1995) "A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion," <i>Journal of Virology</i> , 69(6): 3771-3777

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>22102-002US1</b>	Application No. 09/623,533
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bridon, et al.	
		Filing Date <b>September 5, 2000</b>	Group Art Unit <b>1648</b>

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
	AT	Christodoulou, John et al. "H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys <sup>34", FEBS Letters</sup> 376:pp. 1-5 (1995)	
	AU	Davies, David R. et al. (Jan. 1996) "Interactions of Protein Antigens with Antibodies," Proc. Natl. Acad. Sci. USA, 93:7-12	
	AV	Jiang, Shibo et al. (2002) "Peptide and Non-peptide HIV Fusion Inhibitors," Current Pharmaceutical Design, 8:563-580	
	AW	Jones, Susan et al. (Jan. 1996) "Principles of Protein-Protein Interactions," Proc. Natl. Acad. Sci. USA, 93:13-20	
	AX	Kwong, Peter D. et al. (Feb. 2000) "Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus," Journal of Virology, 74(4):1961-1972	
	AY	Labrijn, Aran F. "Access of Antibody Molecules to the Conserved Coreceptor Binding Site of Glycoprotein gp120..." Journal of Virology, (Oct. 2003), Vol. 77:pp. 10557-10565	
	AZ	Lamber, D.M. et al. "Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion", (Nov. 1995) Medical Sciences, pp. 2186-2191	
	AAA	Lawless, Mary K. et al. (1996) "HIV-1 Membrane Fusion Mechanism: Structural Studies of the Interactions between Biologically-Active Peptides from gp41," Biochemistry, 35: 13697-13708	
	ABB	Narazaki, Ryuichi, et al. "Covalent Binding Between Bucillamine Derivatives and Human Serum Albumin" <i>Pharmaceutical Research</i> , Vol. 13, No. 9; pp. 1317-1321 (1996)	
	ACC	Qureshi, Nasar M. "Characterization of a Putative Cellular Receptor for HIV-1 Transmembrane Glycoprotein Using Synthetic Peptides" AIDS, (1990) Vol. 4:pp. 553-558	
	ADD	Sanders, Roger W. et al. (Sept. 2002) "Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1," Journal of Virology, 76(17) 8875-8889	
	AEE	Shugars, Diane C. et al. (May 1996) "Biophysical Characterization of Recombinant Proteins Expressing the Leucine Zipper-Like Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41," Journal of Virology, 70(5): 2982-2991	
	AFF	Sodroski, Joseph G. "HIV-1 Entry Inhibitors in the Side Pocket", Cell, (Oct. 29, 1999), Vol. 99:pp. 243-246	
	AGG	Tolman, R.L. et al. (1993) "Cyclic V3-Loop-Related HIC-1 Conjugate Vaccines: Synthesis, Conformation and Immunological Properties" <i>Int. J. Peptide Protein Res.</i> 41:455-466	
	AHH	Wang, Ning et al. (Apr. 1995) "Sequence Diversity of V1 and V2 Domains of gp120 from Human Immunodeficiency Virus Type 1: Lack of Correlation with Viral Phenotype," Journal of Virology, 69(4): 2708-2715	
	AII	Wild, Carl "A synthetic Peptide inhibitor of Human Immunodeficiency Virus Replication: Correlation...", Proc. Natl. Acad. Sci., (Nov. 1992) Vol. 89:pp. 10537-10541	
	AJJ	Yang, Xinzhen et al. (May 2000) "Modifications that Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution," Journal of Virology, 74(10): 4746-4754	
	AKK	Decision from Appeal Board dated July 27, 2007	
	ALL	Decision from Opposition Division dated February 1, 2005	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	